GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Cyclically Adjusted Revenue per Share

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Cyclically Adjusted Revenue per Share : ¥3.70 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shenzhenlubris Pharmaceuticals Co's adjusted revenue per share for the three months ended in Mar. 2024 was ¥0.981. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥3.70 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Shenzhenlubris Pharmaceuticals Co's average Cyclically Adjusted Revenue Growth Rate was 1.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shenzhenlubris Pharmaceuticals Co was 10.60% per year. The lowest was 3.50% per year. And the median was 6.15% per year.

As of today (2024-06-10), Shenzhenlubris Pharmaceuticals Co's current stock price is ¥27.26. Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ¥3.70. Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is 7.37.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shenzhenlubris Pharmaceuticals Co was 17.91. The lowest was 5.47. And the median was 8.46.


Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Revenue per Share Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.18 3.30 3.46 3.63 3.66

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.65 3.64 3.67 3.66 3.70

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted PS Ratio falls into.



Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shenzhenlubris Pharmaceuticals Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.981/115.2271*115.2271
=0.981

Current CPI (Mar. 2024) = 115.2271.

Shenzhenlubris Pharmaceuticals Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.613 98.200 0.719
201409 0.636 98.900 0.741
201412 0.866 99.000 1.008
201503 0.749 99.900 0.864
201506 0.831 99.500 0.962
201509 0.860 100.500 0.986
201512 0.855 100.600 0.979
201603 0.870 102.200 0.981
201606 0.929 101.400 1.056
201609 0.896 102.400 1.008
201612 0.957 102.600 1.075
201703 0.930 103.200 1.038
201706 1.020 103.100 1.140
201709 1.027 104.100 1.137
201712 0.999 104.500 1.102
201803 1.085 105.300 1.187
201806 1.069 104.900 1.174
201809 1.197 106.600 1.294
201812 1.054 106.500 1.140
201903 1.146 107.700 1.226
201906 1.090 107.700 1.166
201909 1.145 109.800 1.202
201912 0.832 111.200 0.862
202003 0.808 112.300 0.829
202006 0.671 110.400 0.700
202009 0.591 111.700 0.610
202012 0.622 111.500 0.643
202103 0.741 112.662 0.758
202106 0.545 111.769 0.562
202109 0.863 112.215 0.886
202112 0.741 113.108 0.755
202203 0.867 114.335 0.874
202206 0.628 114.558 0.632
202209 0.832 115.339 0.831
202212 0.857 115.116 0.858
202303 0.799 115.116 0.800
202306 0.699 114.558 0.703
202309 0.707 115.339 0.706
202312 0.812 114.781 0.815
202403 0.981 115.227 0.981

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=27.26/3.7
=7.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shenzhenlubris Pharmaceuticals Co was 17.91. The lowest was 5.47. And the median was 8.46.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Traded in Other Exchanges
N/A
Address
1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines